|Day's Range||33.87 - 34.14|
|52 Week Range||25.55 - 35.04|
|PE Ratio (TTM)||25.53|
|Dividend & Yield||1.90 (5.60%)|
|1y Target Est||N/A|
Novo Nordisk stock popped Tuesday after AstraZeneca said its Type 2 diabetes drug didn't reduce the risk of cardiovascular events in a trial.
New Research Reports for Oracle, Chubb, AstraZeneca & Others
AstraZeneca plc (AZN) announced that it has signed an agreement with Recordati S.p.A, granting commercial rights to Seloken/Seloken ZOK and associated Logimax fixed-dose combination to the latter in European markets.